That's the result of the company's "vulnerability to cheaper generics and its weak roster of experimental medicine...reviving interest in its pursuit of AstraZeneca (AZN) or other deals to fortify its pipeline," Reuters reports.
While many industry watchers expect Pfizer to re-engage with AstraZeneca in coming months, some say the drugmaker should consider targets more focused on biotechnology, Reuters said.
TheStreet Ratings team rates PFIZER INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate PFIZER INC (PFE) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income."